Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luciano Mutti

Showing results (71-80 of 124) with videos related to

Pageof 13
Sort By:
Mutation Research|October 2, 2007
Genetic susceptibility to malignant mesothelioma and exposure to asbestos: the influence of the familial factorDonatella Ugolini, Monica Neri, Marcello Ceppi, et al.
Oncotarget|May 4, 2016
Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cellsMarco Fiorillo, Rebecca Lamb, Herbert B Tanowitz, et al.
The Lancet. Oncology|September 17, 2013
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trialLuana Calabrò, Aldo Morra, Ester Fonsatti, et al.
JAMA Network Open|March 9, 2022
Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural MesotheliomaTomer Meirson, Francesca Pentimalli, Francesco Cerza, et al.
International Journal of Molecular Sciences|August 27, 2021
CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for AutophagyValerio Nardone, Marcella Barbarino, Antonio Angrisani, et al.
The International Journal of Biological Markers|September 30, 2010
Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesotheliomaAlfonso Cristaudo, Rudy Foddis, Alessandra Bonotti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 21, 2011
Sustained expression of steroid receptor coactivator SRC-2/TIF-2 is associated with better prognosis in malignant pleural mesotheliomaCormac J Jennings, Anthony O'Grady, Robert Cummins, et al.
Journal of Translational Medicine|March 11, 2025
A rapid ecologic analysis, confirmed by a case-control study, identifies class I HLA alleles correlated to the risk of COVID-19Pierpaolo Correale, Giovanni Baglio, Roberto Parrella, et al.
Journal of Translational Medicine|December 13, 2022
Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncologyTomer Meirson, Valerio Nardone, Francesca Pentimalli, et al.
Plos One|June 23, 2017
Correction: MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesotheliomaOmbretta Melaiu, Justin Stebbing, Ylenia Lombardo, et al.
Pageof 13

Showing results (71-80 of 124) with videos related to

Sort By:
Pageof 13
Mutation Research|October 2, 2007
Genetic susceptibility to malignant mesothelioma and exposure to asbestos: the influence of the familial factorDonatella Ugolini, Monica Neri, Marcello Ceppi, et al.
Oncotarget|May 4, 2016
Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cellsMarco Fiorillo, Rebecca Lamb, Herbert B Tanowitz, et al.
The Lancet. Oncology|September 17, 2013
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trialLuana Calabrò, Aldo Morra, Ester Fonsatti, et al.
JAMA Network Open|March 9, 2022
Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural MesotheliomaTomer Meirson, Francesca Pentimalli, Francesco Cerza, et al.
International Journal of Molecular Sciences|August 27, 2021
CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for AutophagyValerio Nardone, Marcella Barbarino, Antonio Angrisani, et al.
The International Journal of Biological Markers|September 30, 2010
Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesotheliomaAlfonso Cristaudo, Rudy Foddis, Alessandra Bonotti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 21, 2011
Sustained expression of steroid receptor coactivator SRC-2/TIF-2 is associated with better prognosis in malignant pleural mesotheliomaCormac J Jennings, Anthony O'Grady, Robert Cummins, et al.
Journal of Translational Medicine|March 11, 2025
A rapid ecologic analysis, confirmed by a case-control study, identifies class I HLA alleles correlated to the risk of COVID-19Pierpaolo Correale, Giovanni Baglio, Roberto Parrella, et al.
Journal of Translational Medicine|December 13, 2022
Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncologyTomer Meirson, Valerio Nardone, Francesca Pentimalli, et al.
Plos One|June 23, 2017
Correction: MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesotheliomaOmbretta Melaiu, Justin Stebbing, Ylenia Lombardo, et al.
Pageof 13